inPractice® - Genotype 2 Patients

AASLD/IDSA guidelines recommend glecaprevir/pibrentasvir and sofosbuvir/velpatasvir as the preferred options for genotype 2 HCV–infected patients (Management Guidelines)^{[AASLD-IDSA HCV]}
- Sofosbuvir/velpatasvir/voxilaprevir is the only regimen recommended for genotype 2 HCV–infected patients with sofosbuvir and NS5A inhibitor experience
EASL guidelines recommend DAA-based regimens for patients with genotype 2 HCV infection (Management Guidelines)^{[EASL HCV]}